Stanley Crooke, founder, CEO and chairman of Ionis Pharmaceuticals, has been named the recipient of the E. B. Hershberg Award by the American Chemical Society for significant discoveries in medicinally active substances.
"I am honored to have received this award and it is humbling to be recognized by this prestigious society,” Crooke said. “In the course of my career, I have always focused my efforts on putting the patient first. In keeping with that focus, I was privileged to lead the development efforts of more than 20 marketed drugs. I have invested the last 27 years and counting of my career in founding and leading Ionis Pharmaceuticals to create and advance antisense technology."
Cooke noted that Ionis has two approved drugs, three Phase III drugs nearing commercialization and a large, diverse pipeline of over three dozen innovative medicines. "All of these drugs have the potential to fundamentally change the course of a broad range of diseases," he said. "The opportunity to have led the creation of a novel technology platform that is able to bring significant value to patients today and greater potential to bring even more value in the future has truly been a highlight of my career."
The American Chemical Society will honor Dr. Crooke at its Annual Meeting in San Francisco on April 4 of next year.